A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor
Clinical trial NCT05148442 · TERMINATED
Trial details
- NCT number
- NCT05148442
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-28
- Primary completion
- 2023-06-19
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.